CORD files for premarket FDA approval for cataract treatment lens

Cumming Ophthalmic Research and Development has filed an application for premarket approval with the U.S. Food and Drug Administration for a lens to help treat cataracts. 

Advertisement

The Model SC9 intraocular lens is designed to treat cataract patients with a single focus spherical optic and rigid structure in order to position the optic to provide intermediate vision. 

CORD has filed for the premarket application on the results of 300 patients who’ve received the lens and been monitored for a minimum of one year. 

The lens was designed by Stuart Cumming, MD, who previously designed the patented Crystalens, which was approved by the FDA in 2003.

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.